Skip to main content.

Long Zheng, MD, PhD

Xinglong Zheng portrait
Professor, Pathology and Laboratory Medicine

Department Chair, University of Kansas Medical Center , Pathology and Laboratory Medicine

Professional Background

Dr. Zheng is Russell J. Eilers MD Endowed Professor and Department Chair of Pathology and Laboratory Medicine at The University of Kansas Medical Center. Dr. Zheng completed his medical degree at Nanchang University, China and PhD at University of Vienna, Austria. Following his residency in Pathology and fellowship in Transfusion Medicine and Hemostasis at Barnes-Jewish Hospital, Washington University in St. Louis, Missouri, Dr. Zheng took his first faculty position at the University of Pennsylvania, Philadelphia, PA. He quickly rose to the rank of tenured Associate Professor. Dr. Zheng was recruited to the University of Alabama at Birmingham where he served the Division Director of Laboratory Medicine and attended transfusion medicine service in the Department of Pathology. In early 2020, Dr. Zheng was named the department chair and service chief in Pathology and Laboratory Medicine, the University of Kansas Medical Center, Kansas City, Kansas.

Dr. Zheng's passion has been in providing high-quality patient care, supporting medical and graduate education, and fostering innovative research. Dr. Zheng's research focuses on pathogenesis of thrombotic thrombocytopenic purpura (TTP), a potentially fatal blood disorder. Dr. Zheng and his colleagues have published more than 125 manuscripts in high-profile and peer-reviewed journals and 6 book chapters. Additionally, Dr. Zheng is the standing member of Hemostasis, Thrombosis, and Blood Transfusion (HTBT) study section at the National Institute of Health, associate editors for Journal of Thrombosis and Haemostasis and Archives of Pathology and Laboratory Medicine. Dr. Zheng has mentored three dozen of graduate students, postdoctoral fellows, junior faculty, and physician scientists.

Education and Training
  • PhD, Mol. Cell Biology, University of Vienna, Vienna, Austria
  • MD, Medicine, Nanchang University, Nanchang, Jiangxi
  • Clinical Fellowship, Transfusion Medicine and Hemostasis, Washington University, St. Louis, Missouri
  • Residency, Pathology, Washington University , St. Louis , Missouri
  • Post Doctoral Fellowship, Hematology/Oncology, Washington University , St. Louis, Missouri
  • Post Doctoral Fellowship, Biological Science, Wichita State University, Wichita, Kansas
Licensure, Accreditations & Certifications
  • Medical Liscence , Kansas State Board of Healing Arts



Dr. Zheng's laboratory has been interested in studying the mechanism of normal and abnormal blood coagulation, specifically the pathogenesis and novel therapeutics of immune-mediated thrombotic thrombocytopenic purpura (iTTP). iTTP is a potential fatal blood disorder, resulting from severe deficiency of a plasma ADAMTS13 protease important for proteolytic cleavage of endothelial von Willebrand factor (VWF). Such as cleavage is essential for normal hemostasis. Deficiency of such a protease results in uncontrolled platelet adhesion and aggregation, leading to thrombosis throughout the body. Patients with such a condition is universally fatal unless being treated immediately with plasma exchange that remove autoantibodies and replenish ADAMTS13.

Following are Dr. Zheng's current research projects, which is supported by the National Heart, Lung, and Blood Institute. 1) The biochemistry of ADAMTS13 protease-structure and function relationship; 2) the cofactor-dependent regulation of ADAMTS13 activity; 3) characterization of anti-ADAMTS13 autoantibodies such as allosteric regulation and mechanism of inhibition; 4) the potential environmental triggers and genetic abnormalities in pathogenesis of TTP.

The laboratory employs various cutting-edge technologies, including molecular cloning, PCR, recombinant protein engineering, expression, and purification, as well as microfluidic shear-based assay or intravital microscopic imaging to analyze thrombus formation, leukocyte rolling. Additionally, various animal models (mice and zebrafish), CRISP/Cas9, and single B cell immunoglobulin (Ig) sequencing technology are employed to further understand the pathogenic mechanism of TTP and other thrombotic disorders.

  • Staley, E, Cao, W., J, Pham, H., P, Kim, C., H, Kocher, N., K, Zheng, L, Gangaraju, R, Lorenz, R., G, Williams, L., A, Marques, M., B, Zheng, X., L. 2019. Clinical factors and biomarkers predicting outcome in patients with immune mediated throbotic thrombocytopenic purpura. Haematologica, 104 (1), 166-175
  • McDaniel, J., K, Abdelgawwad, M., S, Hargett, A, Renfrow, M., B, Bdeir, K, Cao, W., J, Cines, D., B, Long, XL. 2019. Human Netrophil Peptide-1 Inhibits Thrombus Formation Under Arterial Flow via Its Terminal Free Cysteine Thiols. Journal of Thrombosis and Haemostasis, 17, 596-606
  • Abdelgawwad, M., S, Cao, W., J, Zheng, L, Kocher, N., K, Williams, L., A, Zheng, XL. 2018. Transfusion of platelets loaded with recombinant ADAMTS13 is efficacious for inhibiting arterial thrombosis associated with thrombotic thrombocytopenic purpura. Arteriosclerosis Thrombosis Vascular Biology, 38 (11), 2731-2743
  • Kumar, M., A, Cao, W, Pham, H., P, Raju, D, Nawalinski, K, Maloney, Wilensky., E, Schuster, J., M, Zheng, XL. 2018. Relative Deficiency of Plasma ADAMTS13 Activity and Elevation of Human. Journal of Nerotrama
  • Joly, B., S, Zheng, XL, Veyradier, A. 2018. Understanding thrombotic microangiopathies in Children. Journal of Intensive Care Medicine
  • Russell, R., T, McDaniel, J., K, Cao, W., J, Shroyer, M, Wagener, B., M, Zheng, XL. 2018. Low Plasma ADAMTS13 Activity is Associated with Coagulopathy, Endothelial Cell. Journal of Thrombosis and Haemostasis, 118 (4), 676-687
  • Staley, E., M, Simmons, S., C, Feldman, A., Z, Lorenz, R., G, Marques, M., B, Williams, L., A, Zheng, XL. 2018. Management of chronic myeloid leukemia in the setting of pregnancy: when is. Transusion, 58 (2), 456-460
  • Qi, J, Wang, J, Chen, J, Su, J, Tang, Y, Wu, X, Ma, X, Chen, F, Ruan, C, Zheng, XL, Wu, D, Han, Y. 2017. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation. Annals of Hematology, 96 (11), 1849-1855
  • Xiao, J, Feng, Y, Li, X, Li, W, Fan, L, Liu, J, Zheng, X, Chen, K, Chen, X, Zhou, X, Zheng, XL, Chen, S. 2017. Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development. Aretiorsclerosis, Thrombosis, and Vascular Biology, 37 (9), 1748-1756
  • Ping, Z, Soni, A, Williams, A., L, Pham, H., P, Basu, M., K, Zheng, XL. 2017. Mutations in Coagulation FActor VIII Are Associated with More Favorable Outcome in Patients with Cutaneous Melanoma. TH Open